Stomach perforation-induced general occlusion/occlusion-like syndrome and stable gastric pentadecapeptide BPC 157 therapy effect.
Cytoprotection
General occlusion/occlusion-like syndrome
Rats
Stable gastric pentadecapeptide BPC 157
Stomach perforation
Therapy
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
21 Jul 2023
21 Jul 2023
Historique:
received:
19
02
2023
revised:
01
06
2023
accepted:
19
06
2023
medline:
8
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
Using rat stomach perforation as a prototypic direct lesion applied in cytoprotection research, we focused on the first demonstration of the severe occlusion/ occlusion-like syndrome induced by stomach perforation. The revealed stomach-induced occlusion/occlusion-like syndrome corresponds to the previously described occlusion/occlusion-like syndromes in rats suffering multicausal pathology and shared severe vascular and multiorgan failure. This general point was particularly reviewed. As in all the described occlusion/occlusion-like syndromes with permanent occlusion of major vessels, peripheral and central, and other similar noxious procedures that severely affect endothelium function, the stable gastric pentadecapeptide BPC 157 was resolving therapy. To reveal the stomach perforation-induced general occlusion/occlusion-like syndrome and BPC 157 therapy effect. The procedure included deeply anesthetized rats, complete calvariectomy, laparotomy at 15 min thereafter, and stomach perforation to rapidly induce vascular and multiorgan failure occlusion/occlusion-like syndrome. At 5 min post-perforation time, rats received therapy [BPC 157 (10 µg or 10 ng/kg) or saline (5 mL/kg, 1 mL/rat) (controls)] into the perforated defect in the stomach). Sacrifice was at 15 min or 60 min post-perforation time. Assessment (gross and microscopy; volume) included: Brain swelling, peripheral vessels (azygos vein, superior mesenteric vein, portal vein, inferior caval vein) and heart, other organs lesions ( BPC 157 beneficial effects accord with those noted before in the healing of the perforated defect (raised vessel presentation; less bleeding, defect contraction) and occlusion/occlusion-like syndromes counteraction. BPC 157 therapy (into the perforated defect), induced immediate shrinking and contraction of the whole stomach (unlike considerable enlargement by saline application). Accordingly, BPC 157 therapy induced direct blood delivery We revealed stomach perforation as a severe occlusion/occlusion-like syndrome, peripherally and centrally, and rapid counteraction by BPC 157 therapy. Thereby, further BPC 157 therapy may be warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Using rat stomach perforation as a prototypic direct lesion applied in cytoprotection research, we focused on the first demonstration of the severe occlusion/ occlusion-like syndrome induced by stomach perforation. The revealed stomach-induced occlusion/occlusion-like syndrome corresponds to the previously described occlusion/occlusion-like syndromes in rats suffering multicausal pathology and shared severe vascular and multiorgan failure. This general point was particularly reviewed. As in all the described occlusion/occlusion-like syndromes with permanent occlusion of major vessels, peripheral and central, and other similar noxious procedures that severely affect endothelium function, the stable gastric pentadecapeptide BPC 157 was resolving therapy.
AIM
OBJECTIVE
To reveal the stomach perforation-induced general occlusion/occlusion-like syndrome and BPC 157 therapy effect.
METHODS
METHODS
The procedure included deeply anesthetized rats, complete calvariectomy, laparotomy at 15 min thereafter, and stomach perforation to rapidly induce vascular and multiorgan failure occlusion/occlusion-like syndrome. At 5 min post-perforation time, rats received therapy [BPC 157 (10 µg or 10 ng/kg) or saline (5 mL/kg, 1 mL/rat) (controls)] into the perforated defect in the stomach). Sacrifice was at 15 min or 60 min post-perforation time. Assessment (gross and microscopy; volume) included: Brain swelling, peripheral vessels (azygos vein, superior mesenteric vein, portal vein, inferior caval vein) and heart, other organs lesions (
RESULTS
RESULTS
BPC 157 beneficial effects accord with those noted before in the healing of the perforated defect (raised vessel presentation; less bleeding, defect contraction) and occlusion/occlusion-like syndromes counteraction. BPC 157 therapy (into the perforated defect), induced immediate shrinking and contraction of the whole stomach (unlike considerable enlargement by saline application). Accordingly, BPC 157 therapy induced direct blood delivery
CONCLUSION
CONCLUSIONS
We revealed stomach perforation as a severe occlusion/occlusion-like syndrome, peripherally and centrally, and rapid counteraction by BPC 157 therapy. Thereby, further BPC 157 therapy may be warranted.
Identifiants
pubmed: 37545637
doi: 10.3748/wjg.v29.i27.4289
pmc: PMC10401663
doi:
Substances chimiques
BPC 157
8ED8NXK95P
Peptide Fragments
0
Anti-Ulcer Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4289-4316Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: Authors declare no conflict of interest.
Références
Eur J Pharmacol. 2016 Jan 15;771:211-9
pubmed: 26698393
J Physiol Pharmacol. 2013 Oct;64(5):597-612
pubmed: 24304574
J Physiol Paris. 2001 Jan-Dec;95(1-6):289-93
pubmed: 11595452
Life Sci. 2022 Dec 1;310:121072
pubmed: 36228773
Eur J Pharmacol. 2019 Oct 15;861:172593
pubmed: 31401154
Oxid Med Cell Longev. 2019 Dec 30;2019:9084643
pubmed: 31976029
Biomedicines. 2022 Dec 04;10(12):
pubmed: 36551886
World J Gastroenterol. 2018 Dec 28;24(48):5462-5476
pubmed: 30622376
J Appl Physiol (1985). 2011 Mar;110(3):774-80
pubmed: 21030672
Eur J Pharmacol. 2016 Dec 15;793:56-65
pubmed: 27815173
Thromb Res. 2012 May;129(5):652-9
pubmed: 21840572
Biomedicines. 2021 Jul 15;9(7):
pubmed: 34356886
Eur J Pharmacol. 1997 Jul 30;332(1):23-33
pubmed: 9298922
Drug Des Devel Ther. 2015 Apr 30;9:2485-99
pubmed: 25995620
Neurosci Bull. 2019 Feb;35(1):167-170
pubmed: 30116973
Biology (Basel). 2021 Sep 09;10(9):
pubmed: 34571768
World J Gastrointest Pathophysiol. 2020 Mar 13;11(1):1-19
pubmed: 32226643
Biomedicines. 2021 Oct 20;9(11):
pubmed: 34829735
J Physiol Pharmacol. 2011 Oct;62(5):527-34
pubmed: 22204800
Curr Med Chem. 2023;30(13):1568-1573
pubmed: 36200148
Regul Pept. 2013 Feb 10;181:50-66
pubmed: 23327997
Surgery. 1997 Aug;122(2):288-94
pubmed: 9288134
Experientia. 1982 Feb 15;38(2):254-6
pubmed: 6120852
Biomedicines. 2021 Jun 28;9(7):
pubmed: 34203464
J Physiol Pharmacol. 2017 Apr;68(2):265-272
pubmed: 28614776
Vascul Pharmacol. 2018 Jul;106:54-66
pubmed: 29510201
Eur J Pharmacol. 2016 Jun 5;780:1-7
pubmed: 26875638
Dig Dis Sci. 2009 Oct;54(10):2070-83
pubmed: 19093208
Curr Pharm Des. 2018;24(18):1990-2001
pubmed: 29879879
Forensic Sci Int. 2021 Apr 29;323:110808
pubmed: 33971505
Biomedicines. 2022 Jan 26;10(2):
pubmed: 35203478
Biomedicines. 2021 Dec 31;10(1):
pubmed: 35052769
Biomedicines. 2021 Jul 08;9(7):
pubmed: 34356860
J Physiol Paris. 2001 Jan-Dec;95(1-6):303-8
pubmed: 11595454
Med Sci Monit Basic Res. 2013 Mar 12;19:93-102
pubmed: 23478678
Emerg Med Int. 2020 May 27;2020:6805354
pubmed: 32566305
J Physiol Pharmacol. 2021 Dec;72(6):
pubmed: 35485358
Biomedicines. 2021 Sep 23;9(10):
pubmed: 34680419
Front Pharmacol. 2021 Dec 13;12:718147
pubmed: 34966273
J Physiol Pharmacol. 2018 Jun;69(3):
pubmed: 30279308
Sci Rep. 2020 Oct 13;10(1):17078
pubmed: 33051481
Curr Pharm Des. 2014;20(7):1126-35
pubmed: 23755725
J Physiol Pharmacol. 2015 Aug;66(4):581-90
pubmed: 26348082
Drug Des Devel Ther. 2020 Dec 21;14:5599-5610
pubmed: 33376304
Curr Pharm Des. 2013;19(1):76-83
pubmed: 22950504
Brain Behav. 2020 Aug;10(8):e01726
pubmed: 32558293
Eur J Pharmacol. 2007 Sep 10;570(1-3):212-21
pubmed: 17628536
PLoS One. 2016 Sep 14;11(9):e0162590
pubmed: 27627764
World J Hepatol. 2020 May 27;12(5):184-206
pubmed: 32547687
Evid Based Complement Alternat Med. 2017;2017:8713561
pubmed: 28250796
Life Sci. 2011 Mar 14;88(11-12):535-42
pubmed: 21295044
J Physiol Pharmacol. 2010 Apr;61(2):241-50
pubmed: 20436226
Curr Pharm Des. 2020;26(25):2991-3000
pubmed: 32329684
Gut Liver. 2020 Mar 15;14(2):153-167
pubmed: 31158953
Biomedicines. 2022 Dec 12;10(12):
pubmed: 36551977
Biomedicines. 2021 Aug 17;9(8):
pubmed: 34440233
Front Pharmacol. 2021 Jun 29;12:627533
pubmed: 34267654
Molecules. 2014 Nov 19;19(11):19066-77
pubmed: 25415472
Inflammopharmacology. 2017 Apr;25(2):255-264
pubmed: 28255738
Eur J Pharmacol. 2019 Mar 15;847:130-142
pubmed: 30690000
Biomedicines. 2022 Oct 25;10(11):
pubmed: 36359218
World J Gastroenterol. 2022 Jan 7;28(1):23-46
pubmed: 35125818
J Pharmacol Sci. 2004 May;95(1):19-26
pubmed: 15153646
Curr Pharm Des. 2017;23(27):4012-4028
pubmed: 28228068
J Pharmacol Sci. 2007 May;104(1):7-18
pubmed: 17452811
J Mol Med (Berl). 2017 Mar;95(3):323-333
pubmed: 27847966
Curr Pharm Des. 2018;24(18):1947-1956
pubmed: 29898649
J Physiol Paris. 1997 May-Oct;91(3-5):139-49
pubmed: 9403788
Curr Pharm Des. 2010;16(10):1224-34
pubmed: 20166993
Gastroenterology. 1985 Jan;88(1 Pt 2):228-36
pubmed: 3871087
Life Sci. 1993;53(18):PL291-6
pubmed: 7901724
Gastroenterology. 1979 Sep;77(3):433-43
pubmed: 456839
Arch Surg. 1970 Oct;101(4):478-83
pubmed: 5457245
Eur J Pharmacol. 2013 Feb 15;701(1-3):203-12
pubmed: 23220707
PLoS One. 2015 Apr 21;10(4):e0123454
pubmed: 25897838
J Physiol Pharmacol. 2009 Dec;60 Suppl 7:107-14
pubmed: 20388953
Gastroenterology. 1979 Oct;77(4 Pt 1):761-7
pubmed: 38173
Eur J Pharmacol. 2011 Sep 30;667(1-3):322-9
pubmed: 21645505
Regul Pept. 2009 Aug 7;156(1-3):83-9
pubmed: 19465062
Curr Neuropharmacol. 2016;14(8):857-865
pubmed: 27138887
J Vet Pharmacol Ther. 2018 Aug;41(4):614-621
pubmed: 29682749
Life Sci. 2016 Mar 1;148:63-70
pubmed: 26872976
J Pharmacol Sci. 2006 Nov;102(3):269-77
pubmed: 17116974
Regul Toxicol Pharmacol. 2020 Jul;114:104665
pubmed: 32334036
Curr Pharm Des. 2018;24(18):1972-1989
pubmed: 29998800
Dig Dis Sci. 2009 Jan;54(1):46-56
pubmed: 18649140
Biomedicines. 2022 Jun 01;10(6):
pubmed: 35740321
World J Gastroenterol. 2016 Nov 7;22(41):9127-9140
pubmed: 27895400
Biomedicines. 2021 Sep 13;9(9):
pubmed: 34572392
Biomedicines. 2021 May 26;9(6):
pubmed: 34073625
Inflammopharmacology. 2017 May 17;:
pubmed: 28516373
Neural Regen Res. 2022 Mar;17(3):482-487
pubmed: 34380875
J Physiol Paris. 2001 Jan-Dec;95(1-6):315-24
pubmed: 11595456
World J Gastroenterol. 2017 Aug 7;23(29):5304-5312
pubmed: 28839430
Curr Pharm Des. 2020;26(25):2971-2981
pubmed: 32445447
Life Sci. 2017 Oct 1;186:66-79
pubmed: 28797793